다형교아종 치료 시장 규모, 점유율과 동향 분석 리포트 : 치료별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 3.72 billion in 2024 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.68% from 2025 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The incidence of GBM is steadily increasing worldwide, driven by both improved diagnostic capabilities and a genuine rise in the number of cases. Particularly concerning is the increasing impact of GBM on aging populations, as the risk of developing the disease escalates with age. With the global geriatric population continuing to grow, the number of GBM cases is projected to increase, placing additional strain on healthcare systems and underscoring the urgent need for more effective treatment options.

Data from healthcare institutions around the world highlight the growing clinical burden of GBM. For instance, in December 2024, Parkway Cancer Centre in Singapore reported approximately 100 new GBM cases annually, emphasizing the significant strain on the country's advanced neuro-oncology infrastructure. GBM patients typically require intensive, multidisciplinary care, involving surgery followed by concurrent radiotherapy and chemotherapy. However, relapses are common within months, highlighting the limitations of current treatment approaches. The center's report underscores the importance of continued advancements in personalized medicine, particularly through the integration of genomics and immunotherapies, to address the complexities of GBM treatment.

Moreover, the integration of advanced technologies in neurosurgery is improving GBM patient outcomes, further boosting treatment access in emerging markets. For example, studies have shown that intraoperative MRI (Io-MRI) significantly enhances surgery success by improving tumor resection rates. A 2024 study published in the Journal of Neuro-Oncology found that Io-MRI-assisted surgeries increased gross total resection rates from 33.6% to 49.6%, with patients experiencing lower recurrence rates and longer progression-free survival.

The therapy's growing global adoption is also being driven by improved access and supportive reimbursement environments. In several countries, health systems have incorporated TTF into covered treatment options, removing financial barriers for eligible patients. By the end of 2024, Novocure reported over 4,000 active patients on its Optune Gio TTF system globally, with significant user numbers in the U.S., Germany, France, and Japan. This growing patient base demonstrates the expanding clinical confidence and acceptance of TTF therapy across both developed and emerging healthcare markets. Additionally, the therapy's success is encouraging further technological refinements and research into new applications beyond GBM. Together, these trends are reshaping the therapeutic landscape, making TTF a key component of future GBM treatment approaches.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Surgery
• Radiation Therapy
• Chemotherapy
  • Temozolomide
  • Lomustine
  • Carmustine Wafers
  • Other
• Targeted Therapy
• Tumor Treating Field (TTF) Therapy
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics / Outpatient Centers
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2033
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
• 4.4. Surgery
  • 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
• 4.5. Radiation Therapy
  • 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
• 4.6. Chemotherapy
  • 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Temozolomide
    • 4.6.2.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Lomustine
    • 4.6.3.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Carmustine Wafers
    • 4.6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Other
    • 4.6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
• 4.7. Targeted Therapy (Bevacizumab)
  • 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End-Use Business Analysis

• 5.1. End-Use Market Share, 2024 & 2033
• 5.2. End-Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
• 5.5. Clinics / Outpatient Centers
  • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
• 5.6. Ambulatory Surgical Centers
  • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Countries Estimates & Trend Analysis

• 6.1. Country Market Share Analysis, 2024 & 2033
• 6.2. Country Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.3.1. U.S.
    • 6.3.1.1. Key Country Dynamics
    • 6.3.1.2. Target Disease Prevalence
    • 6.3.1.3. Regulatory Framework
    • 6.3.1.4. Reimbursement Framework
    • 6.3.1.5. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Reimbursement Framework
    • 6.3.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Reimbursement Framework
    • 6.3.3.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. UK Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Reimbursement Framework
    • 6.4.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Reimbursement Framework
    • 6.4.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Reimbursement Framework
    • 6.4.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Target Disease Prevalence
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Reimbursement Framework
    • 6.4.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Target Disease Prevalence
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Reimbursement Framework
    • 6.4.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Middle East and Africa
  • 6.7.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Target Disease Prevalence
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement Framework
    • 6.7.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Target Disease Prevalence
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Reimbursement Framework
    • 6.7.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Merck & Co., Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Teva Pharmaceutical
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Sun Pharma
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Amneal Pharmaceuticals
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. F. Hoffmann-La Roche Ltd.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Amgen, Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Pfizer Inc.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Arbor Pharmaceuticals (Azurity)
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Karyopharm Therapeutics, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives